$0.50
0.32% yesterday
Nasdaq, Aug 11, 05:48 pm CET
ISIN
US05360L2051
Symbol
ATXI

Avenue Therapeutics, Inc. Stock price

$0.50
+0.14 36.99% 1M
-0.87 63.50% 6M
-1.50 75.00% YTD
-1.99 79.92% 1Y
-327.66 99.85% 3Y
-11,733.25 100.00% 5Y
-9,280.75 99.99% 10Y
-9,280.75 99.99% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.00 0.32%
ISIN
US05360L2051
Symbol
ATXI
Industry

Key metrics

Basic
Market capitalization
$1.6m
Enterprise Value
$-1.9m
Net debt
positive
Cash
$3.5m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.5
Financial Health
Equity Ratio
104.9%
Return on Equity
-428.6%
ROCE
-407.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-9.5m | $-14.5m
Net Income
$-9.2m | $-6.4m
Free Cash Flow
$-7.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
19.7% | -31.6%
Net Income
-27.6% | 47.0%
Free Cash Flow
35.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.1
FCF per Share
$-2.2
Short interest
2.8%
Employees
2
Rev per Employee
$0.0
Show more

Is Avenue Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Avenue Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Avenue Therapeutics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Avenue Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Avenue Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.81 4.81
7% 7%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.49 -9.49
20% 20%
-
Net Profit -9.16 -9.16
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Avenue Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.

Head office United States
CEO Alexandra MacLean
Employees 2
Founded 2015
Website avenuetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today